Aligos Therapeutics Inc (ALGS)
0.82
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
0.82
0.00 (0.00%)
After-Hours: 20:00
Aligos Therapeutics Cash from Operations (Quarterly): -22.66M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -22.66M |
| September 30, 2023 | -20.34M |
| June 30, 2023 | -13.62M |
| March 31, 2023 | -22.39M |
| December 31, 2022 | -16.78M |
| September 30, 2022 | -17.14M |
| June 30, 2022 | -25.04M |
| March 31, 2022 | -20.43M |
| Date | Value |
|---|---|
| December 31, 2021 | -37.48M |
| September 30, 2021 | -25.37M |
| June 30, 2021 | -23.02M |
| March 31, 2021 | -29.80M |
| December 31, 2020 | -19.68M |
| September 30, 2020 | -16.57M |
| June 30, 2020 | -17.69M |
| March 31, 2020 | -20.32M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-37.48M
Minimum
Dec 2021
-13.62M
Maximum
Jun 2023
-21.77M
Average
-20.38M
Median
Cash from Operations (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | -16.62M |
| CEL-SCI Corp | -4.888M |
| AIM ImmunoTech Inc | -9.758M |
| IGC Pharma Inc | -1.587M |
| NovaBay Pharmaceuticals Inc | -0.314M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.007M |
| Cash from Financing (Quarterly) | 87.94M |
| Free Cash Flow | -79.02M |
| Free Cash Flow Per Share (Quarterly) | -0.3018 |
| Free Cash Flow to Equity (Quarterly) | -22.66M |
| Free Cash Flow to Firm (Quarterly) | -21.20M |
| Free Cash Flow Yield | -188.3% |